NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
Ogboche A. Enegela ; Fatima Anjum .
Last Update: April 27, 2023 .
Pyruvate kinase deficiency (PKD) is the most common enzyme-related glycolytic defect that results in red cell hemolysis. Invariably, PKD results in hereditary non-spherocytic anemia. This activity reviews the evaluation and management of pyruvate kinase deficiency and highlights the role of the healthcare team in improving care for patients with this condition.
Review the etiology of pyruvate kinase deficiency. Describe the appropriate evaluation of patients with pyruvate kinase deficiency. Outline the management options available for pyruvate kinase deficiency.Summarize the importance of improving care coordination amongst interprofessional team members to improve outcomes for patients affected by pyruvate kinase deficiency.
Pyruvate kinase deficiency (PKD) is the most common enzyme-related glycolytic defect that results in red cell hemolysis.[1][2][3][4][5] This disorder is characterized by clinical heterogeneity.[5][6] Heterogeneity results in a variable degree of hemolysis, causing irreversible cellular disruption.[6][7][8] Invariably, PKD results in hereditary non-spherocytic anemia.[9][10] Manifestations occur from the neonatal period through adult life.[10] A myriad of complications could arise from hemolytic anemia.[1][9]
Red blood cell (RBC) metabolism hinges on glycolysis. Pyruvate kinase (PK) enzyme is key to this process. PK converts phosphoenolpyruvate to pyruvate.[2] This step yields 50% of RBC ATP. PK modulates NADH production for methemoglobin reduction.[11] These metabolites enable RBCs to function effectively. In PKD, cellular energy efficiency and longevity decrease. Young RBCs are most affected in PKD.[9] PK expression is controlled by the PK-LR gene. The gene is located on chromosome 1q21.[3] PKD follows an autosomal recessive inheritance pattern.[9] Homozygotes and compound heterozygotes are affected. Compound heterozygotes inherit two different mutant alleles.[12] About 300 PKD-causing mutations have been found.[13] The majority of these are missense mutations.[9][13] However, novel mutations have been reported.[14][15] Frameshift, deletion, and insertion type mutations can occur.[16]
PKD was first discovered in 1961 by Valentine et al.[13] Since this discovery, worldwide reports have emerged. PKD is a rare disorder. The true prevalence of PKD is unknown.[4] Estimated PKD prevalence ranges from 3.2 - 8.5 cases per million of the Western population.[10] However, a prevalence of 1:20,000 has been reported.[13][17] Mutant allele frequency may approach 51 per million.[6] Case clusters are found in Brazil and Tunisia.[6][7]
Evidence of PKD-related gender differences appears scarce. Specific mutations have higher frequencies in certain communities, such as Pennsylvania Amish and Romani communities.[9] Certain factors could explain this finding. A founder effect indicates the heritability of mutations. Mutations have been traced to specific migrant couples. In addition, consanguinity increases the risk of homozygosity.[17]
Neonatal RBCs consume more ATP than in adults.[16] Splenic destruction of reticulocytes causes hyperbilirubinemia, and exchange transfusion to prevent kernicterus may be required. Severe anemia in-utero can result in fetal hydrops. Transfusion-dependent neonatal anemia may occur.[1][20]
Dilutional anemia occurs in the second trimester of pregnancy in these patients. Plasma volume increases more than RBC mass.[21] Maternal hemodilution presumably improves fetal outcomes. It also minimizes postpartum blood loss.[22] PKD may exacerbate physiologic anemia of pregnancy.[9][13] Episodic hemolysis may require RBC transfusion replacement.
Manifestations include hyperbilirubinemia and anemia. Surviving neonates have recognizable pallor.[23] Characteristic worsening pallor in the first week occurs. Poor suckling with frequent pauses may occur. Lethargy and poor weight gain may manifest. Tachypnea may indicate heart failure. Hydrops may develop in-utero. Skin edema and birth asphyxia are common. Stillbirth frequently complicates hydrops.[24] Blueberry muffin rashes indicating extramedullary hemopoiesis may occur in these newborns.[13] Yellow skin and sclerae manifest jaundice. Kernicterus may supervene with severe untreated hemolysis.[9][17]
Older Children and Adults
Older children may present with poor growth, easy fatiguability, and jaundice. Some children may have poor appetite and dizziness.[17] Stress may precipitate hemolytic crises. Physical examination shows icterus and conjunctival pallor. Hepatosplenomegaly due to hemolysis occurs. Extramedullary hemopoiesis may result in frontal bossing.[13] Adults may present with complications. These include gall stones, hemosiderosis, and aplastic anemia.
Laboratory evaluation is indicated for neonatal anemia or hyperbilirubinemia. Childhood chronic anemia with splenomegaly warrants investigation. Transfusion-dependent patients require evaluation.[4] Complete blood count characterizes anemia. Hemoglobin levels vary for different severities of PK deficiency. A blood smear shows normochromic cells. Polychromasia with echinocytes may be seen. Spherocytes are absent. Macrocytosis indicates folate deficiency.[3] Reticulocytosis does not correlate with hemolysis.[9] LDH is elevated, and haptoglobin is low. Coombs' test and osmotic fragility are negative. Hemoglobin electrophoresis is normal.
PK activity level is key to the diagnosis. PKD suspicion is warranted with near-normal PK levels. In these cases, adjusted measures are necessary. RBC age-corrected PK enzyme levels are low. Pyruvate kinase/hexokinase activity ratio is also low.[4]
Genetic analysis showing PKLR mutations is diagnostic. Mutation types are elucidated by this method.
Iron overload is a risk in PKD. Regular screening with iron studies may reveal its onset.[25] Hyperferritinemia may herald the onset of iron overload.[9] Magnetic resonance imaging (MRI) for hemosiderosis is useful in selected patients.
Supportive therapy is important in chronic anemia. Folic acid supplementation is advocated for children. Pregnancy and hemolytic crises also warrant supplementation. These states are associated with increased folate demand. Blood transfusion ameliorates anemia. Decisions for transfusion must be justifiable. Good decisions are based on patient-specific presentations, which may prevent iron overload in patients.[25] Increasing intervals between transfusion can reduce risk.[13]
Splenectomy is indicated for massive splenomegaly. This eliminates the risk of traumatic rupture. Severe anemia may also benefit from splenectomy. Total splenectomy is advocated in late childhood. Vaccination for encapsulated bacteria is required post-splenectomy.[13] Prophylactic antibiotics are also beneficial.[26]
Hemosiderosis requires iron-chelation therapy with desferrioxamine. However, this should be stopped before pregnancy.[27]
PKD patients can successfully navigate pregnancy. Pre-pregnancy surveillance for complications is essential. These include viral screening and maternal echocardiography. Appropriate counseling is required before screening tests.[28] Folate supplementation helps prevent fetal malformations. Transfusion should be reserved for symptomatic anemia. A hemoglobin level of less than 8 g/dL also requires transfusion.[27] Management by hematologists and obstetricians is essential. Fetal surveillance is advisable for suspected growth restriction.[28] Preterm delivery occurs in 10% of cases.[25]
The differential diagnoses of PKD include other causes of hemolytic anemia. Immune hemolysis and enzyme deficiencies are considerations. Antibody-mediated hemolysis occurs with blood-group incompatibility. Coombs' positivity characterizes blood-group incompatibility.[18] ABO and Rhesus incompatibility cause hydrops fetalis, whereas neonatal anemia with jaundice occurs in survivors. RBC membrane defects, such as hereditary spherocytosis, can also cause hemolysis. Spherocytes are easily evident on blood smears. Positive family history is usually found. Osmotic red cell lysis is also present. Flow cytometric diagnosis is the gold standard, and decreased ankyrin or spectrin expression is diagnostic.[29]
Glucose-6-phosphate dehydrogenase deficiency is an X-linked recessive condition. It is the most common inherited enzymopathic cause of hemolytic anemia. Males are commonly affected. Rarely, females with lyonization are affected. African-American and Mediterranean heritage is common.[30] Hemolytic triggers include infections, medication, and oxidant stress. History and assaying enzyme activity aid diagnosis.[31]
Prognostication in PKD is highly variable. Disease severity and early care modify outcomes. Severe anemia and hemosiderosis are unfavorable and portend risk, particularly in pregnancy.[9][27]
Complications may arise from hemolysis or therapy. Neonatal hyperbilirubinemia may be the first manifestation.[9] Hemolysis causes iron loading and hemosiderosis. Pigment gall stones commonly complicate PKD, and at least 30% of patients develop cholelithiasis.[13] Transfusions may also result in iron loading. Pre-transfusion screening reduces blood-borne viral transmission. Aplastic anemia from parvovirus B-19 infection is infrequent.[13] Extramedullary hemopoiesis may present with unusual masses. Paravertebral or intraabdominal masses require careful follow-up.[32] Pregnancy may be complicated by growth restriction.[33]
Continuous patient education on infections is essential. Infection prevention may limit hemolytic episodes. Vaccination, prophylactic folate, and antibiotics are pertinent. Premarital education is essential in PKD prevention. Educating prospective couples helps in psychological preparation. Screening partners for carrier status is advisable.[27] Pre-pregnancy evaluation and advice are vital.
Liver failure is unusual in PKD. However, a report has been made. A careful review of other causes is required. Remarkably, PKD may protect against malaria. Studies from Sub-Saharan Africa and Asia are supportive in this regard.[2][34]
PKD frequently poses a diagnostic dilemma. Causes of neonatal hyperbilirubinemia are myriad. Detecting PKD requires careful evaluation. Recently, PKD-specific patient-reported outcome measures were designed. [Level 5][1] This tool requires trials for widespread acceptability. Nonetheless, PKD-specific measurements are necessary. Interprofessional care assures the best outcomes. Hematologist and obstetrician-led pregnancy care are vital. Psychologists can provide patients critical support. Depression screening and prevention should be prioritized. Expert care will identify patients requiring support. Research into oral PK activators is on-going. Gene therapy is possible but not recommended.[13] Surgical management of massive splenomegaly may be required.[9]
Salek S, Boscoe AN, Piantedosi S, Egan S, Evans CJ, Wells T, Cohen J, Klaassen RJ, Grace R, Storm M. Development of the pyruvate kinase deficiency diary and pyruvate kinase deficiency impact assessment: Disease-specific assessments. Eur J Haematol. 2020 May; 104 (5):427-434. [PMC free article : PMC7216839 ] [PubMed : 31880847 ]
Machado P, Manco L, Gomes C, Mendes C, Fernandes N, Salomé G, Sitoe L, Chibute S, Langa J, Ribeiro L, Miranda J, Cano J, Pinto J, Amorim A, do Rosário VE, Arez AP. Pyruvate kinase deficiency in sub-Saharan Africa: identification of a highly frequent missense mutation (G829A;Glu277Lys) and association with malaria. PLoS One. 2012; 7 (10):e47071. [PMC free article : PMC3474807 ] [PubMed : 23082140 ]
Cançado RD. Pyruvate kinase deficiency: novel mutations and a better understanding of the genotype-to-phenotype correlation in Brazilian patients. Rev Bras Hematol Hemoter. 2018 Jan-Mar; 40 (1):1-2. [PMC free article : PMC6002967 ] [PubMed : 29519365 ]
Bianchi P, Fermo E, Glader B, Kanno H, Agarwal A, Barcellini W, Eber S, Hoyer JD, Kuter DJ, Maia TM, Mañu-Pereira MDM, Kalfa TA, Pissard S, Segovia JC, van Beers E, Gallagher PG, Rees DC, van Wijk R., with the endorsement of EuroBloodNet, the European Reference Network in Rare Hematological Diseases. Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. Am J Hematol. 2019 Jan; 94 (1):149-161. [PMC free article : PMC7344868 ] [PubMed : 30358897 ]
Secrest MH, Storm M, Carrington C, Casso D, Gilroy K, Pladson L, Boscoe AN. Prevalence of pyruvate kinase deficiency: A systematic literature review. Eur J Haematol. 2020 Aug; 105 (2):173-184. [PMC free article : PMC7496626 ] [PubMed : 32279356 ]
Svidnicki MCCM, Santos A, Fernandez JAA, Yokoyama APH, Magalhães IQ, Pinheiro VRP, Brandalise SR, Silveira PAA, Costa FF, Saad STO. Novel mutations associated with pyruvate kinase deficiency in Brazil. Rev Bras Hematol Hemoter. 2018 Jan-Mar; 40 (1):5-11. [PMC free article : PMC6003125 ] [PubMed : 29519373 ]
Jaouani M, Manco L, Kalai M, Chaouch L, Douzi K, Silva A, Macedo S, Darragi I, Boudriga I, Chaouachi D, Fitouri Z, Van Wijk R, Ribeiro ML, Abbes S. Molecular basis of pyruvate kinase deficiency among Tunisians: description of new mutations affecting coding and noncoding regions in the PKLR gene. Int J Lab Hematol. 2017 Apr; 39 (2):223-231. [PubMed : 28133914 ]
Radosinska J, Vrbjar N. The role of red blood cell deformability and Na,K-ATPase function in selected risk factors of cardiovascular diseases in humans: focus on hypertension, diabetes mellitus and hypercholesterolemia. Physiol Res. 2016 Sep 19; 65 Suppl 1 :S43-54. [PubMed : 27643939 ]
Grace RF, Zanella A, Neufeld EJ, Morton DH, Eber S, Yaish H, Glader B. Erythrocyte pyruvate kinase deficiency: 2015 status report. Am J Hematol. 2015 Sep; 90 (9):825-30. [PMC free article : PMC5053227 ] [PubMed : 26087744 ]
Chartier ME, Hart L, Paganelli M, Ahmed N, Bilodeau M, Alvarez F. Successful Liver Transplants for Liver Failure Associated With Pyruvate Kinase Deficiency. Pediatrics. 2018 Apr; 141 (Suppl 5):S385-S389. [PubMed : 29610156 ]
Yamada M, Sakai H. Hidden Antioxidative Functions of Reduced Nicotinamide Adenine Dinucleotide Coexisting with Hemoglobin. ACS Chem Biol. 2017 Jul 21; 12 (7):1820-1829. [PubMed : 28485916 ]
Bagla S, Bhambhani K, Gadgeel M, Buck S, Jin JP, Ravindranath Y. Compound heterozygosity in PKLR gene for a previously unrecognized intronic polymorphism and a rare missense mutation as a novel cause of severe pyruvate kinase deficiency. Haematologica. 2019 Sep; 104 (9):e428-e431. [PMC free article : PMC6717571 ] [PubMed : 30948487 ]
Grace RF, Mark Layton D, Barcellini W. How we manage patients with pyruvate kinase deficiency. Br J Haematol. 2019 Mar; 184 (5):721-734. [PubMed : 30681718 ]
Lesmana H, Dyer L, Li X, Denton J, Griffiths J, Chonat S, Seu KG, Heeney MM, Zhang K, Hopkin RJ, Kalfa TA. Alu element insertion in PKLR gene as a novel cause of pyruvate kinase deficiency in Middle Eastern patients. Hum Mutat. 2018 Mar; 39 (3):389-393. [PMC free article : PMC5805577 ] [PubMed : 29288557 ]
Klei TRL, Kheradmand Kia S, Veldthuis M, Beuger BM, Geissler J, Dehbozorgian J, Karimi M, van Bruggen R, van Zwieten R. Residual pyruvate kinase activity in PKLR-deficient erythroid precursors of a patient suffering from severe haemolytic anaemia. Eur J Haematol. 2017 Jun; 98 (6):584-589. [PubMed : 28295642 ]
Steiner LA, Gallagher PG. Erythrocyte disorders in the perinatal period. Semin Perinatol. 2007 Aug; 31 (4):254-61. [PMC free article : PMC2098040 ] [PubMed : 17825683 ]
Christensen RD, Eggert LD, Baer VL, Smith KN. Pyruvate kinase deficiency as a cause of extreme hyperbilirubinemia in neonates from a polygamist community. J Perinatol. 2010 Mar; 30 (3):233-6. [PubMed : 20182430 ]
Nassin ML, Lapping-Carr G, de Jong JL. Anemia in the Neonate: The Differential Diagnosis and Treatment. Pediatr Ann. 2015 Jul; 44 (7):e159-63. [PMC free article : PMC6104389 ] [PubMed : 26171704 ]
Meza NW, Alonso-Ferrero ME, Navarro S, Quintana-Bustamante O, Valeri A, Garcia-Gomez M, Bueren JA, Bautista JM, Segovia JC. Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme. Mol Ther. 2009 Dec; 17 (12):2000-9. [PMC free article : PMC2814388 ] [PubMed : 19755962 ]
Christensen RD, Yaish HM, Nussenzveig RH, Agarwal AM. Siblings with severe pyruvate kinase deficiency and a complex genotype. Am J Med Genet A. 2016 Sep; 170 (9):2449-52. [PubMed : 27354418 ]
Chandra S, Tripathi AK, Mishra S, Amzarul M, Vaish AK. Physiological changes in hematological parameters during pregnancy. Indian J Hematol Blood Transfus. 2012 Sep; 28 (3):144-6. [PMC free article : PMC3422383 ] [PubMed : 23997449 ]
Vricella LK. Emerging understanding and measurement of plasma volume expansion in pregnancy. Am J Clin Nutr. 2017 Dec; 106 (Suppl 6):1620S-1625S. [PMC free article : PMC5701717 ] [PubMed : 29070547 ]
Haley K. Congenital Hemolytic Anemia. Med Clin North Am. 2017 Mar; 101 (2):361-374. [PubMed : 28189176 ]
An X, Wang J, Zhuang X, Dai J, Lu C, Li X, Yan Y. Clinical Features of Neonates with Hydrops Fetalis. Am J Perinatol. 2015 Nov; 32 (13):1231-9. [PubMed : 26070120 ]
van Beers EJ, van Straaten S, Morton DH, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kwiatkowski JL, Rothman JA, Sharma M, Neufeld EJ, Sheth S, Despotovic JM, Kollmar N, Pospíšilová D, Knoll CM, Kuo K, Pastore YD, Thompson AA, Newburger PE, Ravindranath Y, Wang WC, Wlodarski MW, Wang H, Holzhauer S, Breakey VR, Verhovsek M, Kunz J, McNaull MA, Rose MJ, Bradeen HA, Addonizio K, Li A, Al-Sayegh H, London WB, Grace RF. Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica. 2019 Feb; 104 (2):e51-e53. [PMC free article : PMC6355506 ] [PubMed : 30213831 ]
Jones AD, Khan M, Cheshire J, Bowley D. Postsplenectomy Prophylaxis: A Persistent Failure to Meet Standard? Open Forum Infect Dis. 2016 Oct; 3 (4):ofw197. [PMC free article : PMC5152704 ] [PubMed : 27975073 ]
Dolan LM, Ryan M, Moohan J. Pyruvate kinase deficiency in pregnancy complicated by iron overload. BJOG. 2002 Jul; 109 (7):844-6. [PubMed : 12135225 ]
Mohamed S, Sivarajah K, Chakravarti S. A case of severe pyruvate kinase deficiency in a primigravida: successful outcome. Obstet Med. 2013 Jun; 6 (2):90-91. [PMC free article : PMC5052770 ] [PubMed : 27757165 ]
Iolascon A, Avvisati RA, Piscopo C. Hereditary spherocytosis. Transfus Clin Biol. 2010 Sep; 17 (3):138-42. [PubMed : 20655264 ]
Bubp J, Jen M, Matuszewski K. Caring for Glucose-6-Phosphate Dehydrogenase (G6PD)-Deficient Patients: Implications for Pharmacy. P T. 2015 Sep; 40 (9):572-4. [PMC free article : PMC4571844 ] [PubMed : 26417175 ]
Satyagraha AW, Sadhewa A, Elvira R, Elyazar I, Feriandika D, Antonjaya U, Oyong D, Subekti D, Rozi IE, Domingo GJ, Harahap AR, Baird JK. Assessment of Point-of-Care Diagnostics for G6PD Deficiency in Malaria Endemic Rural Eastern Indonesia. PLoS Negl Trop Dis. 2016 Feb; 10 (2):e0004457. [PMC free article : PMC4760930 ] [PubMed : 26894297 ]
Shaikh H, Bakalov V, Shaikh S, Amjad A. Paravertebral Mass and Diffuse Lymphadenopathy in a Patient with Pyruvate Kinase Deficiency: Malignancy or Alternative Etiology? Cureus. 2019 Jun 06; 11 (6):e4849. [PMC free article : PMC6684121 ] [PubMed : 31410332 ]
Wax JR, Pinette MG, Cartin A, Blackstone J. Pyruvate kinase deficiency complicating pregnancy. Obstet Gynecol. 2007 Feb; 109 (2 Pt2):553-5. [PubMed : 17267892 ]
van Bruggen R, Gualtieri C, Iliescu A, Louicharoen Cheepsunthorn C, Mungkalasut P, Trape JF, Modiano D, Sirima BS, Singhasivanon P, Lathrop M, Sakuntabhai A, Bureau JF, Gros P. Modulation of Malaria Phenotypes by Pyruvate Kinase (PKLR) Variants in a Thai Population. PLoS One. 2015; 10 (12):e0144555. [PMC free article : PMC4677815 ] [PubMed : 26658699 ]
Disclosure: Ogboche Enegela declares no relevant financial relationships with ineligible companies.
Disclosure: Fatima Anjum declares no relevant financial relationships with ineligible companies.
